In light of the recent MSKCC Phase 2 data indicating reduced skeletal events with treatment, how will you approach management of patients with asymptomatic bone mets?
How will you approach patients with diffuse metastases who you would have otherwise deferred treatment?
Answer from: Radiation Oncologist at Community Practice
It sounds promising, but there is not enough information about the cohort for me to make an informed assessment. One problem I have is that bone metastases from different primary malignancies really shouldn't be grouped together. It's a good starting point for more investigation, and I look forward ...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
I think the full manuscript will be of strong interest. I do think that seeing the improvement in SRE's even when 'needs RT' was excluded makes it a point worth considering for those protocol defined high-risk patients.
While I do currently already offer 'prophylactic palliation' in the spine for s...
Comments
Radiation Oncologist at Stroger Hospital
Full manuscript would be highly informative.
Full manuscript would be highly informative.